Increased or synergistic apoptosis induction arising from the combination of proteasome inhibitors and death ligands have been described in conventional GBM cells line models, such as U87MG and T98G cells treated with the proteasome inhibitor MG132 or bortezomib and recombinant human TRAIL [18, 19]. Here, TNFSF10 is linked to glioblastoma.